Other Events ·
Nasdaq notifies Enlivex of non-compliance with the $1.00 minimum bid price requirement
ENLVEnlivex Ltd.
The Nasdaq Stock Market notified Enlivex that its ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days ending October 22, 2026. Because Enlivex executed a reverse split within the prior year, it is ineligible for the standard 180-day cure period. The company has implemented a 1-for-16 reverse stock split effective immediately and intends to appeal the delisting determination via an oral hearing before the Nasdaq Hearings Panel. Trading will continue during the appeal process, though success is not guaranteed. Enlivex operates in the biotechnology sector, developing immunotherapies for aging-related conditions while maintaining a digital asset treasury.